Volume 22 Issue 7
Jul.  2024
Turn off MathJax
Article Contents
Article Navigation >  Chinese Journal of General Practice  > 2024  >  22(7): 1138-1141
LING Nengyong, WANG Sheng. Evaluation of prognosis in patients with high-grade non-muscle invasive bladder cancer using systemic inflammatory response index[J]. Chinese Journal of General Practice, 2024, 22(7): 1138-1141. doi: 10.16766/j.cnki.issn.1674-4152.003584
Citation: LING Nengyong, WANG Sheng. Evaluation of prognosis in patients with high-grade non-muscle invasive bladder cancer using systemic inflammatory response index[J]. Chinese Journal of General Practice, 2024, 22(7): 1138-1141. doi: 10.16766/j.cnki.issn.1674-4152.003584
shu

Evaluation of prognosis in patients with high-grade non-muscle invasive bladder cancer using systemic inflammatory response index

doi: 10.16766/j.cnki.issn.1674-4152.003584

  • Department of Urology, the First Affiliated Hospital of Bengbu Medical University, Bengbu, Anhui 233004, China

Funds:

 1808085MH293

  • Received Date: 2024-01-26
    Available Online: 2024-09-05
    Abstract
  •   Objective  The systemic inflammatory response index (SIRI) was used to evaluate the prognosis of high-grade non-muscle invasive bladder cancer (NMIBC) patients, which provided new ideas and theoretical value for the diagnosis and treatment of patients with high-grade NMIBC.  Methods  A total of 40 cases with high-grade NMIBC who underwent transurethral resection of bladder tumor (TURBT) in the First Affiliated Hospital of Bengbu Medical University from January 1, 2019 to January 1, 2020 were analyzed retrospectively. According to whether the patient has a tumor recurrence after surgery, the working subjects operated the characteristic curve (ROC) to determine the best cutoff value of SIRI and divided it into high-value group and low-value group, so as to determine the influence on the prognosis of high-grade NMIBC patients.  Results  The ROC curve of SIRI to predict prognosis (with or without recurrence) is drawn, and the best cut-off value of SIRI was 1.46. According to the optimal cut-off value, patients were divided into high SIRI group (SIRI≥1.46, 18 cases) and low SIRI group (SIRI < 1.46, 22 cases). Tumor size varied in the distribution between the high and low SIRI groups. Patients with high SIRI were more likely to have a 3 cm maximum tumor diameter before surgery. Survival analysis showed that there were significant differences in SIRI, tumor number, and recurrence-free survival (RFS) during different size of tumors. The survival of patients with low SIRI was better than that of patients with high SIRI. Patients with single tumor were better than patients with multiple tumors, and patients with maximum tumor diameter less than 3 cm were better than patients with tumor diameter more than 3 cm. Cox univariate analysis confirmed that SIRI, tumor number, and tumor size were independent influencing factors for postoperative RFS in the advanced group. Cox multivariate analysis confirmed that SIRI more than 1.46 was an independent risk factor for postoperative RFS in NMIBC patients.  Conclusion  SIRI can be used as a risk assessment index for patients with high-grade NMIBC, which can provide new options and directions for the treatment of high-grade NMIBC.

     

    • FullText(HTML)
  • loading
    • References(21)
  • [1]
    张永琪, 邹震海, 吴梦琦, 等. 敲低EPHA2通过mTOR磷酸化调控膀胱癌细胞自噬和生物学行为[J]. 中华全科医学, 2023, 21(7): 1117-1120, 1129. doi: 10.16766/j.cnki.issn.1674-4152.003063

    ZHONG Y Q, ZOU Z H, WU M Q, et al. Knockdown of EPHA2 regulates autophagy and biological behavior of bladder cancer cell through mTOR phosphorylation[J]. Chinese Journal of General Practice, 2023, 21(7): 1117-1120, 1129. doi: 10.16766/j.cnki.issn.1674-4152.003063
    [2]
    SUNG H, FERLAY J, SIEGEL R L, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249. doi: 10.3322/caac.21660
    [3]
    BABJUK M, BURGER M, CAPOUN O, et al. European association of urology guidelines on non-muscle-invasive bladder cancer (Ta, T1, and carcinoma in situ)[J]. Eur Urol, 2021, 81(1): 75-94.
    [4]
    PYRGIDIS N, VOLZ Y, EBNER B, et al. The effect of hospital caseload on perioperative mortality, morbidity and costs in bladder cancer patients undergoing radical cystectomy: results of the German nationwide inpatient data[J]. World J Urol, 2024, 42(1): 19. DOI: 10.1007/s00345-023-04742-z.
    [5]
    VAISHNAV M, GARG S, ADHADUK B. Association of smoking, p53 and Ki-67 immunomarkers with bladder neoplasms in tribal region of India[J]. Int J Health Sci(Qassim), 2022, 16(6): 11-17.
    [6]
    HU H P, LAI S C, WANG M R, et al. Effect of subsequent bladder cancer on survival in upper tract urothelial carcinoma patients post-radical nephroureterectomy: a systematic review and meta-analysis[J]. BMC Urol, 2023, 23(1): 212. DOI: 10.1186/s12894-023-01387-3.
    [7]
    WANG P. Evaluation of the effect of transurethral resection of bladder tumors in the treatment of bladder cancer and its impact on CA19-9 and CA125 levels[J]. Urol Res, 2023, 1(3): 17-22. doi: 10.26689/ur.v1i3.5986
    [8]
    HOOGEVEEN F, BLANKER M H, CAUBERG E, et al. Recurrence of non-muscle invasive bladder carcinoma after transurethral resection with hexaminolevulinate photodynamic diagnosis or regular cystoscopy[J]. Scand J Urol, 2023, 58: 120-125. doi: 10.2340/sju.v58.10160
    [9]
    WARAICH T A, KHALID S Y, ALI A, et al. Comparative outcomes of radical cystectomy in muscle-invasive bladder cancer: a systematic review and meta-analysis[J]. Cureus, 2023, 15(12): e50646. DOI: 10.7759/cureus.50646.
    [10]
    ABBATE V, BARONE S, BORRIELLO G, et al. Diagnostic performance of inflammatory biomarkers and cytological analysis in salivary gland tumors[J]. Head neck, 2023, 45(12): 3015-3023. doi: 10.1002/hed.27528
    [11]
    ZHANG Y Y, LI W Q, LI Z F, et al. Higher levels of pre-operative peripheral lymphocyte count is a favorable prognostic factor for patients with stage Ⅰ and Ⅱ rectal cancer[J]. Front Oncol, 2019, 9: 960. DOI: 10.3389/fonc.2019.00960.
    [12]
    ALAME M, PIREL M, COSTES-MARTINEAU V, et al. Characterisation of tumour microenvironment and immune checkpoints in primary central nervous system diffuse large B cell lymphomas[J]. Virchows Arch, 2020, 476(6): 891-902. doi: 10.1007/s00428-019-02695-6
    [13]
    SHADPOUR P, ZAMANI M, AGHAALIKHANI N, et al. Inflammatory cytokines in bladder cancer[J]. J Cell Physiol, 2019, 234(9): 14489-14499. doi: 10.1002/jcp.28252
    [14]
    NIEDERBERGER E, MÖLLER M, MUNGO E, et al. Distinct molecular mechanisms contribute to the reduction of melanoma growth and tumor pain after systemic and local depletion of alpha-synuclein in mice[J]. FASEB J, 2023, 37(12): e23287. DOI: 10.1096/fj.202301489R.
    [15]
    WIGNER P, GREBOWSKI R, BIJAK M, et al. The interplay between oxidative stress, inflammation and angiogenesis in bladder cancer development[J]. Int J Mol Sci, 2021, 22(9): 4483. DOI: 10.3390/ijms22094483.
    [16]
    SHAH M A, ROGOFF H A. Implications of reactive oxygen species on cancer formation and its treatment[J]. Semin Oncol, 2021, 48(3): 238-245. doi: 10.1053/j.seminoncol.2021.05.002
    [17]
    ZHU H H, LIU Y T, FENG Y, et al. Circulating tumor cells (CTCs)/circulating tumor endothelial cells (CTECs) and their subtypes in small cell lung cancer: predictors for response and prognosis[J]. Thorac Cancer, 2021, 12(20): 2749-2757. doi: 10.1111/1759-7714.14120
    [18]
    DO M H, SHI W, JI L L, et al. Reprogramming tumor-associated macrophages to outcompete endovascular endothelial progenitor cells and suppress tumor neoangiogenesis[J]. Immunity, 2023, 56(11): 2555-2569. e5. doi: 10.1016/j.immuni.2023.10.010
    [19]
    WANG X, JIA Y, WEN L, et al. Porphyromonas gingivalis promotes colorectal carcinoma by activating the hematopoietic NLRP3 inflammasome[J]. Cancer Res, 2021, 81(10): 2745-2759. doi: 10.1158/0008-5472.CAN-20-3827
    [20]
    CHEN Z, WANG K, LU H, et al. Systemic inflammation response index predicts prognosis in patients with clear cell renal cell carcinoma: a propensity score-matched analysis[J]. Cancer Manag Res, 2019, 11: 909-919. doi: 10.2147/CMAR.S186976
    [21]
    HUA X, LONG Z Q, HUANG X, et al. The preoperative systemic inflammation response index (SIRI) independently predicts survival in postmenopausal women with breast cancer[J]. Curr Probl Cancer, 2020, 44(4): 100560. DOI: 10.1016/j.currproblcancer.2020.100560.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(4)  / Tables(3)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (55) PDF downloads(7) Cited by()
    Proportional views
    Related

    Address：No. 287, Changhuai Road, Bengbu, Anhui Province, 233004, P.R.ChinaphoneNo：0552-3066635； 0552-3051890Email：zhqkyx@163.com

    Copyright © Chinese Journal of General Practice皖ICP备2020018345号-2

    Supported by: Beijing Renhe Information Technology Co., Ltd.    

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return